Medication info
Lopin Plus Tablet (Losartan Potassium, Hydrochlorothiazide)

Lopin Plus Tablet (Losartan Potassium, Hydrochlorothiazide)

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›50mg / 1 tabletHydrochlorothiazide›12.5mg / 1 tablet
Manufacturer / importer
Taegeuk Pharmaceutical Co., Ltd.
Appearance
Yellow oval film-coated tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200607818 · Notified 2006.10.26 · Insurance code 644800540

Summary

Main use
Treatment of hypertension not controlled by monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is observed approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start treatment with this medicine only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: This medicine may be substituted for combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure being controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment who require dose adjustment, because the initial losartan potassium dose of 25 mg cannot be administered with this medicine.
Child dose
Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Taegeuk Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled by monotherapy

  • Hypertension
View approved original text

In patients with hypertension who are not adequately controlled with monotherapy, this medication effectively lowers blood pressure and helps reduce the risk of cardiovascular complications. It maintains stable blood pressure to support a healthy lifestyle.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. In general, the maximum blood pressure-lowering effect is observed approximately 3 weeks after starting treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start treatment with this medicine only when the expected effect has not been achieved with monotherapy. 1. Substitution therapy: This medicine may be substituted for combination therapy with individually dose-adjusted losartan potassium and hydrochlorothiazide. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who develop hypokalemia despite blood pressure being controlled at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which can reduce the dose of hydrochlorothiazide without reducing the overall blood pressure-lowering effect. Continue to assess the clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg; if blood pressure is not controlled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or higher. Use of this medicine is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Use of this medicine is not recommended in patients with hepatic impairment who require dose adjustment, because the initial losartan potassium dose of 25 mg cannot be administered with this medicine.

Child dose

Children (under 18 years) There is no experience with use in children and adolescents; therefore, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus when taken during pregnancy, especially in the second and third trimesters. Discontinue use immediately if pregnancy is confirmed. Patients with hypersensitivity, certain electrolyte imbalances, or severe liver or kidney dysfunction should not take this medication. Patients with hypotension or kidney function problems, as well as those with a history of liver disease, should take this medication with caution and undergo regular blood tests and health checks during treatment. As this medication lowers blood pressure, symptoms such as dizziness, drowsiness, and orthostatic hypotension may occur, so caution is needed when driving or operating machinery. Do not take potassium supplements or potassium-containing salt substitutes without consulting a physician while on this medication; inform healthcare providers about any other medications to avoid potential interactions. Due to the hydrochlorothiazide component, the skin may become sensitive to sunlight, so avoid sun exposure, and consult a physician immediately if any skin abnormalities occur. Safety and efficacy of this medication in pediatric and adolescent populations have not been established, so it is not used in these groups. Elderly patients may experience more frequent adverse reactions while taking this medication, requiring careful monitoring by healthcare providers. If any adverse reactions occur during treatment, consult a physician immediately, especially for symptoms of hypotension, edema, rash, or respiratory distress, which require prompt action. Store this medication out of the reach of children, and keep it sealed in its original container.

Side effects

  • Craniosynostosis
  • anuria
  • hypotension
  • renal failure
  • death
  • abdominal pain
  • edema
  • palpitations
  • back pain
  • dizziness
Show 128 more
  • cough
  • sinusitis
  • upper respiratory tract infection
  • rash
  • angioedema
  • skin desquamation
  • hemolysis
  • chest pain
  • facial edema
  • fever
  • orthostatic hypotension
  • syncope
  • angina
  • arrhythmia
  • cerebrovascular accident
  • myocardial infarction
  • secondary atrioventricular block
  • loss of appetite
  • constipation
  • toothache
  • dry mouth
  • dyspepsia
  • flatulence
  • gastritis
  • vomiting
  • fatigue
  • anemia
  • gout
  • arm pain
  • arthralgia
  • arthritis
  • fibromyalgia
  • hip pain
  • joint swelling
  • knee pain
  • leg pain
  • muscle cramps
  • muscle weakness
  • musculoskeletal pain
  • myalgia
  • shoulder pain
  • muscle rigidity
  • anxiety
  • anxiety disorders
  • ataxia
  • confusion
  • depression
  • nightmares
  • sensory loss
  • insomnia
  • decreased libido
  • memory impairment
  • migraine
  • hypersensitivity
  • panic disorder
  • sensory abnormality
  • peripheral neuropathy
  • sleep disorders
  • drowsiness
  • tremors
  • dyspnea
  • epistaxis
  • nasal congestion
  • pharyngeal discomfort
  • respiratory congestion
  • rhinitis
  • venous sinus disorder
  • chest discomfort
  • alopecia
  • dermatitis
  • dry skin
  • petechiae
  • erythema
  • flushing
  • photosensitivity reaction
  • pruritus
  • sweating
  • urticaria
  • blurred vision
  • ocular pain
  • burning sensation
  • conjunctivitis
  • vision impairment
  • taste abnormality
  • tinnitus
  • erectile dysfunction
  • nocturia
  • polyuria
  • urinary tract infection
  • weakness
  • pancreatitis
  • jaundice
  • sialadenitis
  • convulsions
  • gastrointestinal irritation
  • aplastic anemia
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • purpura
  • necrotizing vasculitis
  • pneumonia
  • pulmonary edema
  • acute respiratory distress syndrome
  • hyperglycemia
  • diabetes
  • muscle cramps
  • restlessness
  • renal failure
  • renal dysfunction
  • interstitial nephritis
  • skin and mucous membrane syndrome
  • erythema multiforme
  • toxic epidermal necrolysis
  • transient blurred vision
  • xanthopsia
  • acute myopia
  • acute angle-closure glaucoma
  • choroidal effusion
  • vasculitis
  • anaphylactic reaction
  • hepatitis
  • intestinal vascular edema
  • dry cough
  • erythroderma
  • hyperkalemia
  • hyponatremia
  • rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that does not allow light in. Maintain storage temperature between 1 and 30 degrees Celsius to preserve the effectiveness and safety of the medication.

Appearance and packaging

Appearance

Yellow oval film-coated tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.